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Infestation with head lice is a widespread, persistent, and recurring issue leading to serious health problems if untreated. We are
facing resistance phenomena to usual pediculicides and questions about their direct or cumulative toxicity. The aim of this trial was
to assess the eﬃcacy of a new product, free of chemical insecticides but with a physical eﬀect. This product contains components
whose antilice eﬃcacy has already been demonstrated, as well as Andiroba oil which asphyxiates the lice and Quassia vinegar
which dissolves the chitin of the nits (they are then inactivated). 30 patients with head lice infestation, aged 3–39 years, applied
the treatment one to three times, 5 days apart. Cure was defined as the absence of live lice after 5, 10, or 14 days, and symptoms
are usually associated with infestation. Easiness and safety of the treatment were assessed by the patients and/or their parents.
Overall cure rates were 20% on D5 after one treatment, 37% on D10 after two treatments, and 90% on D14 after three treatments.
Symptoms such as itch, scalp dryness, redness, and flakiness rapidly diminished. This treatment seems to be a beneficial addition or
a valuable alternative to existing treatments, considering the total absence of chemical insecticides, the absence of drug-resistance
induction in head lice, the absence of major toxicological risks compared with usual pediculicides, and the favourable patient use
instructions.
1. Introduction
Head lice (Pediculus humanus capitis) are wingless insects
which are only found as parasites on humans and which
nourish themselves solely from blood [1]. The head louse
lays long pale gray to reddish-brown oval-shaped eggs (nits),
size 0.3–0.8mm. The female attaches the eggs to the hair,
about 1–3 cm from the scalp, at the neck or behind the ears
by preference, using strong water-proof cement. In one day
they can lay up to 10 eggs, giving a life span potential of up
to 300 eggs in their life time (30 to 40 days) [2, 3]. The larvae
hatch within 7–10 days into a nymph or immature louse,
which will die if a human blood meal is not acquired within
24 hours, and 8–10 days later are sexually mature. Thus a new
generation is born within 18 to 24 days [4].
Agents currently approved by the US Food and Drug
Administration for the treatment of head lice infestation are
lindane, malathion, and permethrin cre`me rinse. Because of
the development of resistance, other treatments have been
considered such as trimethoprim, sulfamethoxazole, mala-
thion, ivermectin and carbamyl, as well as combinations
of these agents [5]. Today, the main treatments used
are chemical agents such as pyrethrin (0.3%), malathion
(organophosphate, M96), carabaryl, and permethrin (syn-
thetic pyrethroid) [4, 6, 7]. The reference drug is usually
permethrin [8, 9], which has been found to have the greatest
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eﬃcacy and widest margin of safety, although the usual
frequency of local irritative symptoms observed with perme-
thrin ranges from 2.1% to 5.9% [10]. In the US, Lindane
(1%, an organochloride) is now designated a “second-line”
treatment, meaning it can only be prescribed when other
“first-line” treatments have failed or cannot be used [11]. In
Europe, lindane-containing medications have been removed
from the market since 2007.
Moody and Ritter have underlined in 1989 [12] that the
relatively high permeability of the forehead is important to
note when considering that these insecticides are applied to
the scalp for scabies control and that the human scalp and
forehead have similar permeability. In order to decrease the
toxic risk, some authors have already shown the interest to
shorten the duration of exposure to the treatment to reduce
its skin absorption [13].
Thus even if they are generally considered safe for occa-
sional use, these treatments may pose a greater risk of direct
or cumulative toxicity if used repeatedly and frequently [14–
16]. Additional reasons to investigate alternative products are
failure of current chemical treatments to kill embryos in eggs,
environmental and food safety, and potential toxicity of the
chemical pediculicides. There is a real need for compounds
eﬀectively killing adult lice and eggs by new modes of
action. The benefit of essential oils in the control of head
lice has been quoted since ancient times but few clinical
studies have been published. Veal [17] tested in vitro the
potential eﬀectiveness of many essential oils and suggested an
association of essential oil/vinegar/water to improve eﬃcacy
[17]. The combination of vinegar and water has been shown
to loosen the hold and enhance removal [4]. A new approach,
killing head lice by suﬀocation, has been described by
Pearlman [18], who reported excellent clinical results with a
so-called dry-on suﬀocation-based pediculicide (DSP; [18]).
It was also shown in 2007 that dimethicone killed lice (in
vitro) within 5 minutes, leading to a possible mode of action
of low viscosity silicones by penetration into the spiracles and
causing asphyxia and death [19]. Several promising reports
have been subsequently published introducing new topical
head lice compounds based on this mode of action [20–22].
The new product under study has been developed to treat
hair and scalps aﬄicted by nits and head lice of children
over 3 years of age and adults. It does not contain any
chemical insecticide but rather has a physical eﬀect. It is
an entirely natural product (activates extracted from plants,
no silicone) combining two active principles with eﬀects on
both nits and lice at the same time. The lice are asphyxiated
by Andiroba oil. The Quassia vinegar dissolves the chitin of
the nits, which are then inactivated. Additional components
with demonstrated antilice eﬃcacy are also included (Cocos
nucifera, Thymus vulgaris; [23, 24]).
The objectives of the study were to assess the eﬃcacy of
this product as well as the time needed to cure the patients.
Up to now, this product was used on D0 and applications
repeated after 7 or 14 days if necessary. Buxton [25] has
shown that a treatment is more eﬀective if it is repeated after
10 days because eggs hatch 6 to 10 days after oviposition.
This allows to eradicate the maximum number of lice on
the head between the two treatments and while the lice are
hatching from the eggs, an additional treatment on day 5 is
recommended. This study was conducted in order to test if
applications on D0, D5, and/or D10 would be suﬃcient to
cure the patients within 14 days (last visit).
2. Material and Methods
This was a monocentre open interventional study of the
eﬃcacy and safety of a new product for treatment of head
lice (Rausch Laus-Stop; Rausch AG Kreuzlingen, 8280 Kreu-
zlingen, Switzerland). 30 patients (29 female and one male
patient aged 10.1 ± 7.2 years old (range 3 to 39 y; including
2 adults 25 and 39 y)) were recruited. The volunteers or one
of the parents (or responsible relative) signed an informed
consent after having carefully paid attention to themodalities
and the aim of the study. A specific information note was
prepared for the children in order to explain to them the
aim and the main principles of these studies. It was asked
to family members or fellow pupils who were in close
contact to people with head lice to protect themselves from
a possible lice infestation and to use a shampoo provided by
the sponsor to wash their hair at home (RAUSCH Willow
Bark Shampoo; Rausch AG Kreuzlingen, 8280 Kreuzlingen,
Switzerland). The same shampoo was also provided to the
patients. Clothing, bedding, brushes, combs, and personal
items had to be deloused as well (by washing articles on a
hot cycle or by deep-freezing).
Exclusion criteria were subjects aﬀected by scalp disor-
ders, history of irritation or sensitivity to pediculicides or
hair care products, treatment with a pediculicide within 4
weeks prior to the study, having used hair dyes, bleaches,
permanent wave, or relaxing solutions within the past 2
weeks or during the study. The study was approved by the
local Ethics Committee (CPP Est II) and was notified to the
French Authorities AFSSAPS.
To assess the eﬃcacy of the product accurately all patients
were put in the same conditions: they received a shampoo to
wash their hair at home, after every visit in the Dermatology
Department and one or two times a week. (RAUSCHWillow
Bark Shampoo; Rausch AG Kreuzlingen, 8280 Kreuzlingen,
Switzerland). For patients with long hair, a detangling
spray was also provided (“Rausch Herbal Detangling Spray”;
Rausch AG Kreuzlingen, 8280 Kreuzlingen, Switzerland). It
was applied on the 10-centimeter lower end of the hair
(without rinsing) to make combing easier. These products
were the only ones allowed as hair treatments during the
study and were used according to the instructions of the
manufacturer.
The head lice treatment was performed every five days
until cure by applying generously over the whole scalp,
completely covering the hair roots, especially behind the ears
and on the neck after ensuring that the scalp and hair were
dry. The product was left on for 45min, whereas if needed
the head could be covered with a protective cap. This was
the case for children, who could then freely move during this
time. Thereafter, the product was rinsed oﬀ with plenty of
warm water. The nits were carefully combed out and the hair
was dried.
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Table 1: Patients’ cure rate (%) after treatment.
Infestation (n = 30) D0 D5 D10 D14
0 (no louse) 0 (0%) 6 (20%) 11 (37%) 27 (90%)
1 (light/<10 lice) 9 (33%) 20 (67%) 19 (63%) 3 (10%)
2 (moderate/between 10 and 20 lice) 11 (37%) 4 (13%) 0 (0%) 0 (0%)
3 (severe/>20 lice) 10 (30%) 0 (0%) 0 (0%) 0 (0%)
Table 2: Cure rates, defined as absence of live lice for the intent to treat population (ITT) as well as per protocol (PP).
Infestation
ITT PP
Cured/total % (95% CI) Cured/total % (95% CI)
D5 6/30 20 (9.5–37.3%) 6/30 20 (9.5–37.3%)
D10 11/30 37 (21.9–54.5%) 9/27 33.3 (18.6–52.2%)
D14 27/30 90 (74.4–96.6%) 25/27 92.6 (76.6–98.0%)
The eﬃcacy of the treatment was judged by the disap-
pearance of head lice and nits after one (D0), two (D0 and
D5), or three applications (D0, D5 and D10). The last visit
was scheduled on D14.
The primary outcome measure was the cure rate, defined
as the percentage of patients cured after application of the
treatment. Determination of the cure rate was performed
by the investigator on the basis of visual inspection for
viable nymphs, hatching nymphs, and adult lice (with a ×10
magnifying lens), using a head lice detection comb. The lice
were counted and the infestation was scored as none (= 0),
light (<10 lice) (= 1), moderate (between 10 and 20) (= 2),
or severe (>20 lice) (= 3). A patient was cured if the score was
0 (no live lice) or failed if the score was 1 or higher (one or
more live lice).
The secondary outcome measures were as follows.
(i) Intensity of pruritus on a Visual Analogical Scale
(VAS).
(ii) Clinical scoring of dryness, redness, irritation, and
flakiness (0 = absence, 1 = light, 2 = moderate, 3 =
severe).
(iii) Clinical scoring of irritation, discomfort, and itching
in order to assess the side eﬀects of the product (0 =
absence, 1 = light, 2 = moderate, 3 = severe).
(iv) In case of children being treated, at each visit the par-
ent’s opinion was recorded regarding the workload
required to perform the treatment. The parents were
also questioned about any irritation, discomfort,
embarrassment, or other symptoms associated with
the use of this treatment.
3. Results
3 patients did not come back for the visit of D10. Two of
them did not come because they felt cured (the D5 visit
suggested that they were), and an exam finally performed
on D14 showed that they were indeed cured. Two further
patients did not come back on D14 because they were cured
on D10 and one further patient did not come back without
providing any explanation.
Analyses were performed on Per Protocol as well as on
Intend to Treat population, that is, patients totally withdrawn
were considered as not cured, and missing data on D10 were
replaced as follows: if patients were scored cured on D5 and
D14, they were considered cured on D10, if not, the worst
score (from D5 or D14) was taken for D10.
Figure 1 and Table 1 show the primary outcome (cure
rate). Table 2 describes the evolution of the cure rate for
the whole population (ITT) or the Per Protocol (PP). After
one product application (D5 score), 6 patients were cured
(score 0). After two applications (D10 score), 11 patients
were considered to be free of live lice (37%) and the other
showed only light infestation. However, nits were still present
in 93% of the evaluated patients, but the absence of re-
infestation on D14 suggests that these nits were dead. Finally,
after three applications (D14 score), a total of 27 patients
(90%) were free of lice.
One patient showed a new infestation on D14. This
patient had no lice on D10 but was treated because some
nits were still present. This reinfestation could be explained
by transmission from her sister who also participated in the
study and was still infested on D10.
Clinical scoring of symptoms usually associated with lice
infestation such as itch, scalp dryness, redness (indicative of a
possible inflammation), and flakiness rapidly diminished on
treatment. Itch intensity decreased considerably from 7.3 to
3.7 in five days; and then disappeared in almost 60% of the
patients (data not shown). OnDay 14, only two patients were
still experiencing a significant pruritus although one of these
two patients presented no lice (but it could be explained by
the fact he had dry hair). All other objective and subjective
associated symptoms were similarly considerably decreased
and almost disappeared on Day 14.
All patients found the infestation decreased or disap-
peared during the treatment. Three patients complained of
slight scalp itching or exhibited head scratching after one or
two applications. Three adverse events occurred, which were
not attributable to the treatment.
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0
2
D0 D5 D10 D14
Infestation
No louse
Moderate 
(between 10 and 20 lice)
Light (<10 lice) 1
Severe (>20 lice) 3
Figure 1: Patients’ infestation over treatment period (mean ± standard deviation).
4. Discussion
Up to now, products used in the control of head lice,
including DDT and organochloride insecticides, may be
considered relatively toxic and moreover, problems of tox-
icity and resistance have occurred so that the use of these
products had to be discontinued [25]. In the last decades,
as a result of extensive use, resistance to pediculicides with
a neurotoxic mode of action has increased, particularly
to permethrin [26–34]. Moreover, cross-resistance between
some products such as permethrin and DDT or Bioallethrin
has appeared. Permethrin has been used almost exclusively
for louse control during some times [2]. Although pyrethrins
were nearly 100% eﬀective in the 1980s, recent studies
suggest that this eﬃcacy has decreased up to 50% [32].
Like pyrethrins, clinical failure rates of more than 50% have
been reported with permethrin [26]. Similarly, Mumcuoglu
et al. have reported that a 4-fold decrease in susceptibility
to permethrin at the LT50 level was observed between 1989
and 1994 in Israel [35]. Resistances have been also reported
to DDT, lindane, pyrethrins, permethrin, malathion, and
carbaril.
This phenomenon now extends worldwide and several
possible resistance mechanisms have been reported [36, 37].
Bouvresse et al. have suggested that the uncontrolled use of
pyrethroids should have induced the selection of lice having
homozygous kdr mutations [38]. They have demonstrated
in a study completed in 74 elementary schools in Paris in
2012 that 98.7% of the tested lice had such mutations. Even
if the presence of these mutations may not correlate with
treatment failure, an already strongly established insecticide
has been revealed. Many factors may play a role: for example
the residual activity of permethrin is still suﬃcient to
kill lice 2 weeks after application. This implies that lice
are exposed also during a significant period to sublethal
doses of insecticides, exerting a strong selection pressure for
insecticide resistance. Carbamates and organophosphorus
preparations such as malathion have then be used with
the advantages of being ovicidal as well as insecticidal, in
time the head louse has developed resistance to these newer
agents [39]. Now combinations of many insecticides are
used [40]. Considering the composition of the test product,
which is free of chemical insecticides and acts physically
on lice (asphyxiated by the Andiroba oil) and nits (Quassia
vinegar damages the chitin of the nits), the results of
the study are very interesting. It should not lead to any
resistance phenomenon and bears a far lower toxic risk than
comparable insecticidal treatments.
In addition, treatments are often a burden for the patients
and their family. Some treatments must remain a long
time on the scalp before being washed out (e.g., 12 hours
for malathion). Mumcuoglu [2] mentioned that suﬀocating
agents such as olive, soya, sunflower and corn oils, hair gels,
and mayonnaise are able to kill a significant number of lice
only if they are applied in liberal quantities for more than 12
hours [2]. Asphyxiating treatments with silicone oil [21, 31,
41] require to be left to dry naturally for 8 hours then washed
with a commercial shampoo. This has to be compared with
a maximum of 3 times 45min every 5 days with the test
product, which therefore may be considered much more
patient friendly and should ensure better compliance. This
is important for curing infestation.
On the whole, this cosmetic treatment has thus demon-
strated its interest, with an eﬃcacy which is similar or better
than standard insecticidal treatments [27, 36]. This new
scalp and hair treatment against head lice is free of chemical
insecticides, contain natural ingredients, and act physically
on lice. Its side eﬀects are unusual: in exceptional cases there
may be the occurrence of redness, dry skin, or flakiness.
In comparison with the leader products, the costs of the
treatments are customary in the market, with additional
benefits for the scalp and without detrimental influence on
the hair. It has shown a good eﬃcacy after one, two, or three
applications 5 days apart over a whole treatment period of 14
days. Three treatments were necessary for complete relief in
severe cases. The symptoms associated with lice infestation
such as itch, scalp dryness, and flakiness were rapidly and
greatly decreased by the treatment.
It may therefore be concluded that this new treatment
is a beneficial addition or a valuable alternative to the
existing ones, considering the total absence of chemical
insecticides, the absence of drug resistance induction in head
lice, the absence of major toxicological risks related to classic
pediculicides, and the favourable patient use instructions.
This should be particularly beneficial in children, who
constitute the majority of the population to be treated for
infestation with head lice.
Acknowledgment
This research was funded by Rausch AG.
ISRN Dermatology 5
References
[1] R. C. Hansen, “Overview: the state of head lice management
and control,” The American Journal of Managed Care, vol. 10,
no. 9, pp. S260–S263, 2004.
[2] K. Y. Mumcuoglu, “Prevention and treatment of head lice in
children,” Paediatric Drugs, vol. 1, no. 3, pp. 211–218, 1999.
[3] C. M. McCage, S. M. Ward, C. A. Paling, D. A. Fisher, P. J.
Flynn, and J. L. McLaughlin, “Development of a paw paw
herbal shampoo for the removal of head lice,” Phytomedicine,
vol. 9, no. 8, pp. 743–748, 2002.
[4] F. Sokoloﬀ, “Identification and management of pediculosis,”
Nurse Practitioner, vol. 19, no. 8, pp. 62–64, 1994.
[5] R. B. Hipolito, F. G. Mallorca, Z. O. Zuniga-Macaraig, P. C.
Apolinario, and J. Wheeler-Sherman, “Head lice infestation:
single drug versus combination therapy with one percent
permethrin and trimethoprim/sulfamethoxazole,” Pediatrics,
vol. 107, no. 3, pp. 1–5, 2001.
[6] S. W. Lindsay and S. Peock, “Insecticides against headlice in
Glasgow,” Journal of the Royal Society of Health, vol. 113, no. 4,
pp. 181–183, 1993.
[7] C. Courtiade, C. Labreze, I. Fontan, A. Taı¨eb, and J. Maleville,
“La pe´diculose du cuir chevelu: enqueˆte par questionnaire
dans quatre groupes scolaires de l’acade´mie de Bordeaux en
1990-1991,” Annales de Dermatologie et de Venereologie, vol.
120, pp. 363–368, 1993.
[8] P. Hensel, “The challenge of choosing a pediculicide,” Public
Health Nursing, vol. 17, no. 4, pp. 300–304, 2000.
[9] M. Tanyuksel, R. E. Araz, A. Albay, and H. Aycicek, “Preva-
lence and treatment of Pediculus humanus capitis with 1%
permethrin and 0.4% d-phenothrin in Turkey,” Acta Medica,
vol. 46, no. 2, pp. 73–75, 2003.
[10] E. B. Andrews,M. C. Joseph,M. J. Magenheim, H. H. Tilson, P.
A. Doi, and M. W. Schultz, “Postmarketing surveillance study
of permethrin creme rinse,” American Journal of Public Health,
vol. 82, no. 6, pp. 857–861, 1992.
[11] Y. C. Ha, J. M. Heo, H. J. Kim et al., “Infestation status
of head louse and treatment with lindane shampoo in
children of primary school and kindergarten in Chinju-shi,
Kyongsangnam-do, Korea,” Korean Journal of Parasitology, vol.
38, no. 1, pp. 41–43, 2000.
[12] R. P. Moody and L. Ritter, “Dermal absorption of the insecti-
cide lindane (1δ, 2δ, 3β, 4δ, 5δ, 6β-hexachlorocyclohexane) in
rats and rhesus monkeys: eﬀect of anatomical site,” Journal of
Toxicology and Environmental Health, vol. 28, no. 2, pp. 161–
169, 1989.
[13] R. M. Brand, A. R. Charron, and R. E. Brand, “Decreasing
malathion application time for lice treatment reduces trans-
dermal absorption,” International Journal of Pharmaceutics,
vol. 301, no. 1-2, pp. 48–53, 2005.
[14] T. F. Fischer, “Lindane toxicity in a 24-year-old woman,”
Annals of Emergency Medicine, vol. 24, no. 5, pp. 972–974,
1994.
[15] C. Paget, S. Menard, I. Wroblewski, J. P. Gout, V. Danel, and
M. Bost, “Poisoning by organophosphate insecticides used as
a hair-rinse against lice,” Archives de Pediatrie, vol. 9, no. 9, pp.
913–916, 2002.
[16] F. Menegaux, A. Baruchel, Y. Bertrand et al., “Household
exposure to pesticides and risk of childhood acute leukaemia,”
Occupational and Environmental Medicine, vol. 63, no. 2, pp.
131–134, 2006.
[17] L. Veal, “The potential eﬀectiveness of essential oils as
a treatment for headlice, Pediculus humanus capitis,”
Complementary Therapies in Nursing & Midwifery, vol. 2, no.
4, pp. 97–101, 1996.
[18] D. L. Pearlman, “A simple treatment for head lice: dry-on,
suﬀocation-based pediculicide,” Pediatrics, vol. 114, no. 3, pp.
e275–e279, 2004.
[19] F. A. S. Oliveira, R. Speare, and J. Heukelbach, “High in vitro
eﬃcacy of Nyda L, a pediculicide containing dimeticone,”
Journal of the European Academy of Dermatology and Venere-
ology, vol. 21, no. 10, pp. 1325–1329, 2007.
[20] G. Scanni and E. Bonifazi, “Eﬃcacy and safety of a new non-
pesticide lice removal product,” European Journal of Pediatric
Dermatology, vol. 15, no. 4, pp. 249–252, 2005.
[21] J. Heukelbach, D. Pilger, F. A. Oliveira, A. Khakban, L. Ariza,
and H. Feldmeier, “A highly eﬃcacious pediculicide based on
dimeticone: randomized observer blinded comparative trial,”
BMC Infectious Diseases, vol. 8, article 115, 2008.
[22] J. Heukelbach, A. Asenov, O. Liesenfeld, A. Mirmohammad-
sadegh, and F. A. Oliveira, “A new two-phase dimeticone
pediculicide shows high eﬃcacy in a comparative bioassay,”
BMC Dermatology, vol. 9, article 12, 2009.
[23] D. V. Canyon and R. Speare, “A comparison of botanical
and synthetic substances commonly used to prevent head lice
(Pediculus humanus var. capitis) infestation,” International
Journal of Dermatology, vol. 46, no. 4, pp. 422–426, 2007.
[24] M. Connolly, K. A. Staﬀord, G. C. Coles, C. C. Kennedy,
and A. M. R. Downs, “Control of head lice with a coconut-
derived emulsion shampoo,” Journal of the European Academy
of Dermatology and Venereology, vol. 23, no. 1, pp. 67–69, 2009.
[25] P. A. Buxton, The Louse: An Account of the Lice which Infest
Man, Their Medical Importance and Control, Arnold, London,
UK, 3rd edition, 1950.
[26] J. W. Maunder, “Resistance to organochlorine insecticides in
head lice and trials using alternative compounds,” Medical
Oﬃcer’s, vol. 125, pp. 27–29, 1971.
[27] C. E. Malcolm and J. N. Bergman, “Trying to keep ahead of
lice: a therapeutic challenge,” Skin Therapy Letter, vol. 11, no.
10, pp. 1–6, 2006.
[28] V. Rupes, J. Moravec, J. Chmela, J. Ledvinka, and J. Zelenkova,
“A resistance of head lice (Pediculus capitis) to permethrin in
Czech Republic,” Central European Journal of Public Health,
vol. 3, no. 1, pp. 30–32, 1995.
[29] T. L. Meinking, C. M. Clineschmidt, C. Chen et al., “An
observer-blinded study of 1% permethrin creme rinse with
and without adjunctive combing in patients with head lice,”
Journal of Pediatrics, vol. 141, no. 5, pp. 665–670, 2002.
[30] I. F. Burgess, E. R. Brunton, and N. A. Burgess, “Clinical
trial showing superiority of a coconut and anise spray over
permethrin 0.43% lotion for head louse infestation,” European
Journal of Pediatrics, vol. 169, no. 1, pp. 55–62, 2010.
[31] A. M. R. Downs, K. A. Staﬀord, L. P. Hunt, J. C. Ravenscroft,
and G. C. Coles, “Widespread insecticide resistance in head
lice to the over-the-counter pediculocides in England, and the
emergence of carbaryl resistance,” British Journal of Derma-
tology, vol. 146, no. 1, pp. 88–93, 2002.
[32] J. Heukelbach and H. Feldmeier, “Ectoparasites—the under-
estimated realm,” The Lancet, vol. 363, no. 9412, pp. 889–891,
2004.
[33] C. G. Burkhart and C. N. Burkhart, “Safety and eﬃcacy of
pediculicides for head lice,” Expert Opinion onDrug Safety, vol.
5, no. 1, pp. 169–179, 2006.
[34] M. Kristensen,M. Knorr, A.M. Rasmussen, and J. B. Jespersen,
“Survey of permethrin and malathion resistance in human
head lice populations from Denmark,” Journal of Medical
Entomology, vol. 43, no. 3, pp. 533–538, 2006.
6 ISRN Dermatology
[35] J. M. Clark, “Determination, mechanism and monitoring
of knockdown resistance in permethrin-resistant human
head lice, Pediculus humanus capitis,” Journal of Asia-Pacific
Entomology, vol. 12, no. 1, pp. 1–7, 2009.
[36] K. Y. Mumcuoglu, J. Hemingway, J. Miller et al., “Permethrin
resistance in the head louse Pediculus capitis from Israel,”
Medical and Veterinary Entomology, vol. 9, no. 4, pp. 427–447,
1995.
[37] C. L. Bartels, K. E. Peterson, and K. L. Taylor, “Head lice resis-
tance: Itching that just won’t stop,”Annals of Pharmacotherapy,
vol. 35, no. 1, pp. 109–112, 2001.
[38] S. Bouvresse, Z. Berdjane, R. Durand, J. Bouscaillou, A. Izri,
and O. Chosidow, “Permetrhin and malathion resistance in
head lice: results of ex vivo and molecular assays,” Journal of
the American Academy of Dermatology. In press.
[39] M. Lebwohl, L. Clark, and J. Levitt, “Therapy for head lice
based on life cycle, resistance, and safety considerations,”
Pediatrics, vol. 119, no. 5, pp. 965–974, 2007.
[40] K. Y. Mumcuoglu, J. Miller, C. Zamir, G. Zentner, V. Helbin,
and A. Ingber, “The in vivo pediculicidal eﬃcacy of a natural
remedy,” Israel Medical Association Journal, vol. 4, no. 10, pp.
790–793, 2002.
[41] F. M. De Sousa, A. W. Vasconcelos, J. De Nadon, and P. Y.
Duhot, “Treatment of human head lice infestations in a single
application with a new galenic lotion,” International Journal of
Cosmetic Science, vol. 32, no. 5, pp. 369–375, 2010.
Submit your manuscripts at
http://www.hindawi.com
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013
The Scientific 
World Journal
International Journal of
Endocrinology
Hindawi Publishing Corporation
http://www.hindawi.com
Volume 2013
ISRN 
Anesthesiology
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com
Oncology
Journal of
Volume 2013
PPAR
Resea rch
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
ISRN 
Allergy
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
BioMed Research 
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Obesity
Journal of
ISRN 
Addiction
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Computational and 
Mathematical Methods 
in Medicine
ISRN 
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Clinical &
Developmental
Immunology
Hindawi Publishing Corporation
http://www.hindawi.com
Volume 2013
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
ISRN 
Biomarkers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
MEDIATORS
INFLAMMATION
of
